Danaher Corporation (丹纳赫公司) - Global Life Sciences and Diagnostics Innovator

Company Profile (Updated April 2026)

Danaher Corporation (丹纳赫公司) is a leADINg global life Sciences and diagnostics innovator committed to accelerating the power of science and technology to improve human health. Founded in 1969 and headquartered in Washington, D.C., USA, the company is listed on the New York Stock Exchange (NYSE: DHR).

Danaher operates through three business segments: Biotechnology (bioprocessing and discovery tools), Life Sciences (research instruments, consumAbles, and software), and Diagnostics (clinical instruments, consumables, and services). The company's businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world.

Core Mission: To help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop, and deliver life-changing therapies. The company is powered by the Danaher Business System (DBS), a proven operational excellence framework that drives innovation, productivity, and continuous improvement.

2026 Q1 Financial Performance

Key Results (Three Months Ended March 27, 2026)

Revenue: $5.951 billion, up 3.5% year-over-year

Core Revenue Growth (Non-GAAP): 0.5% year-over-year

Net Earnings: $1.029 billion, or $1.45 per diluted share

Adjusted Diluted EPS (Non-GAAP): $2.06, up 9.5% year-over-year

Gross Profit: $3.591 billion

Operating Profit: $1.344 billion

Operating Cash Flow: $1.3 billion

Free Cash Flow (Non-GAAP): $1.1 billion

R&D Expenses: $387 million

SG&A Expenses: $1.860 billion

Effective Tax Rate: Approximately 16.7%

Average Diluted Shares Outstanding: 711.2 million

Segment Performance (Q1 2026)

Biotechnology: Continued strength in bioprocessing, with robust commercial monoclonal antibody production and gradual improvement in R&D spending

Life Sciences: Better-than-expected performance, with acceleration in China

Diagnostics: Lighter-than-typical Q1 respiratory season at Cepheid offset by solid clinical and applied end market performance

2026 Full-Year Outlook

Core Revenue Growth: 3% to 6% (unchanged from prior guidance)

Adjusted Diluted EPS: $8.35 to $8.55 (raised from previous $8.35-$8.50)

Q2 2026 Core Revenue: Expected to increase in the low-single digit percent range year-over-year

Q2 2026 Adjusted Operating Profit Margin: Approximately 26.5%

Respiratory Revenue Outlook: Approximately $1.6 billion to $1.7 billion for full year 2026

Expected 2026 Free Cash Flow: More than $5 billion

Amortization of Acquisition-Related Intangible Assets: Estimated $1.7 billion for 2026

2025 Full-Year and Q4 Performance

Q4 2025 Results

Revenue: $6.84 billion, up 4.5% year-over-year

Net Earnings: $1.2 billion, or $1.66 per diluted share

Adjusted Diluted EPS: $2.23, up 4.0% year-over-year

Operating Cash Flow: $2.1 billion

Free Cash Flow: $1.8 billion

Full-Year 2025

Adjusted Diluted EPS: $7.70 to $7.80 (at the high end of guidance range)

Full-Year Free Cash Flow: Approximately $5.5 billion

Major Strategic Transaction — Masimo Acquisition (February 2026)

On February 17, 2026, Danaher announced a definitive agreement to acquire Masimo Corporation (NASDAQ: MASI) for approximately $9.9 billion in an all-cash transaction.

Transaction Details:

- Acquisition Price: Approximately $9.9 billion in cash

- Expected Closing: Second half of 2026

- Strategic Rationale: Expands Danaher's portfolio into mission-critical pulse oximetry and patient monitoring solutions in acute care settings

- Expected Synergies: Opportunities to enhance Masimo's performance through the Danaher Business System (DBS) and Danaher's global scale

- Financing: Supported by Danaher's strong balance sheet and robust free cash flow generation (expected >$5 billion in 2026)

Business Segments and Key Brands

Biotechnology

Provides equipment, consumables, and services primarily used to advance and accelerate the research, development, manufacture, and delivery of biological medicines.

- Pall Corporation: Filtration and separation technologies for biopharmaceutical manufacturing

- Cytiva: Chromatography, cell culture media, and bioprocess technologies

- Xcellerex: X-platform bioreactors for bioprocessing

Life Sciences

Offers instruments, consumables, services, and software used to study the basic building blocks of life, including DNA, RNA, proteins, metabolites, and cells.

- Beckman Coulter Life Sciences: Centrifugation, particle counting, and liquid handling

- Sciex: Mass spectrometry and capillary electrophoresis solutions

- Leica Microsystems: Microscopy and imaging systems

- Molecular Devices: Bioanalytical systems for drug discovery and life science research

- Phenomenex: Chromatography consumables

- IDT (Integrated DNA Technologies): Genomic solutions

Diagnostics

Offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions.

- Beckman Coulter Diagnostics: Clinical chemistry, immunoassay, and hematology systems

- Cepheid: Molecular diagnostics and PCR-based infectious disease testing

- Leica Biosystems: Anatomic pathology and workflow solutions

- Radiometer: Blood gas and acute care diagnostics

- HemoCue: Point-of-care hematology testing

Corporate History and Strategic Transformations

Founding and Early Growth (1969-2000s)

Danaher was founded in 1969 as a real estate investment trust and transformed into an industrial manufacturing company. The name "Danaher" is derived from the Danaher Creek in Montana, where the founders fished.

DBS (Danaher Business System)

The Danaher Business System is the company's proprietary operational excellence framework, combining Kaizen principles with strategic growth tools. DBS drives continuous improvement across all businesses and is a key differentiator in Danaher's acquisition and integration strategy.

Major Divestitures and Portfolio Refocusing

- 2015: Acquired Pall Corporation for approximately $13.8 billion, significantly expanding bioprocessing capabilities

- 2016: Acquired Cepheid for approximately $4 billion, strengthening molecular diagnostics

- 2019: Spun off the Dental segment (KaVo Kerr, Nobel Biocare, Ormco) into Envista Holdings Corporation (NYSE: NVST)

- 2023: Spun off the Environmental & Applied Solutions segment into Veralto Corporation (NYSE: VLTO), completing Danaher's transformation into a pure-play life sciences and diagnostics company

Technology and Innovation

AI and Digital Health: Danaher believes the emerging opportunity in AI will further accelerate the pharmaceutical development and commercialization flywheel, improving success rates, lowering development costs, and driving increased demand for life sciences and bioprocessing solutions.

Productivity Initiatives:

- 2025: Targeted $175 million in productivity initiatives, yielding $75 million in net savings

- 2026: Projected $250 million in savings, contributing approximately $0.30 tailwind to EPS

- Expected to drive more than 100 basis points of adjusted operating profit margin improvement in 2026

Global Presence and Workforce

Employees: Approximately 60,000 associates worldwide (as of Q1 2026), down from 63,000 in 2025

Geographic Presence: Operations in 60+ countries worldwide

Key Geographic Trends (Q1 2026):

- china: Acceleration in Life Sciences and Biotechnology businesses

- North America and Europe: Stable performance in clinical and applied end markets

- Middle East: Limited direct revenue or supply chain exposure; monitoring potential pressures from sustained conflict

Company Basic Information

Corporate Overview

Company Full Name: Danaher Corporation (丹纳赫公司)

Founded: 1969

Headquarters: 1201 Wilson Boulevard, Suite 200, Arlington, Virginia 22209, USA (Washington, D.C. metropolitan area)

Stock Exchange: New York Stock Exchange (NYSE)

Stock Ticker: DHR

Company Type: Public Listed Company (S&P 500 Component)

Industry: Life Sciences / Diagnostics / Biotechnology

Employees: Approximately 60,000 (as of Q1 2026)

CEO / President: Rainer M. Blair

Executive Chairman of the Executive Committee: Mitchell P. Rales

CFO / EVP: Matthew McGrew

Chief Science Officer / SVP: Josecarlos Gutierrez-Ramos

General Counsel / SVP: Brian W. Ellis

Official Website: www.danaher.com

Investor Relations: investors.danaher.com

Dividend Information

Quarterly Dividend: $0.40 per share (as of April 2026)

Dividend Yield: Approximately 0.7%

Major Shareholders (As of December 2025)

- The Vanguard Group: 60.97 million shares (8.63% stake)

- Mitchell P. Rales (Executive Chairman): Significant individual holding

2026 Outlook and Strategic Priorities

Strategic Focus Areas

- Bioprocessing Growth: Capitalize on robust demand in commercial monoclonal antibody production and R&D spending recovery

- Diagnostics Recovery: Navigate lighter respiratory seasonality while expanding Cepheid installed base and assay menu

- Life Sciences Acceleration: Leverage improving trends in pharma, biotech, and academic/government research spending

- AI Integration: Explore AI-driven opportunities to accelerate pharma development, improve diagnostic accuracy, and enhance operational efficiency

- Masimo Integration: Complete the $9.9 billion acquisition and apply DBS to drive performance improvement in patient monitoring

- Margin Expansion: Execute $250 million productivity savings to drive >100 bps adjusted operating margin improvement

- Capital Deployment: Utilize strong balance sheet and >$5 billion free cash flow for value-creating M&A and shareholder returns

Competitive Advantages

- Danaher Business System (DBS): Proven operational excellence framework driving consistent margin expansion and integration success

- Pure-Play Focus: Following 2023 Veralto spin-off, fully focused on high-growth life sciences and diagnostics markets

- Portfolio Breadth: Leading positions across bioprocessing, molecular diagnostics, clinical diagnostics, and life sciences research tools

- Balance Sheet Strength: Robust free cash flow generation and capacity for large-scale strategic acquisitions

- Innovation Leadership: Continuous investment in R&D and new product development across all segments

Risk Factors

- China Exposure: Ongoing pricing pressure and policy uncertainty in Chinese diagnostics market, though abating

- Respiratory Seasonality: Cepheid respiratory revenue subject to seasonal and pandemic-related volatility

- Macroeconomic Sensitivity: Biotech funding cycles and academic research budgets impact Life Sciences demand

- Integration Risk: Masimo acquisition execution and realization of expected synergies

- Geopolitical: Potential indirect impacts from Middle East conflict and global trade tensions

Contact Information

Global Headquarters

Address: 1201 Wilson Boulevard, Suite 200, Arlington, Virginia 22209, USA
   Website: www.danaher.com
   Investor Relations: investors.danaher.com

Investor and Media Inquiries

Investor Relations: +1-202-828-0850
   Media: media@danaher.com

Keywords: Danaher Corporation,丹纳赫,DHR,NYSE,Life Sciences,Diagnostics,Biotechnology,Bioprocessing,Cepheid,Beckman Coulter,Leica Biosystems,Sciex,Pall,Cytiva,Masimo,Rainer Blair,Mitchell Rales,DBS,Danaher Business System,Washington DC,Arlington,Virginia,Envista,Veralto,Pall Acquisition,Cepheid Acquisition,Masimo Acquisition,AI Diagnostics,Free Cash Flow,Core Revenue Growth